Summary Using a doxorubicin-resistant subline (K562/ADM) of human leukaemia K562 cells (Tsuruo et al, 1986) , the effect of immunoliposomes that targeted a cellular transferrin receptor (TFR) was examined by neutralization of doxorubicin (DOX) resistance. OKT9-CIL, prepared by conjugation of DOX-encapsulated liposome with an anti-TFR monoclonal antibody, OKT9 (Aisenberg and Wilkes, 1980) , showed similar binding to both K562 and K562/ADM. Although an 80-fold higher sensitivity to free DOX on cell growth inhibition in K562 than in K562/ADM was found, the difference was clearly diminished after OKT9-CIL treatment through the increased sensitivity of K562/ADM. The cellular DOX level 30 min after the exposure of free DOX was 45-fold lower in K562/ADM than in K562, whereas nearly equivalent DOX levels were detected in K562 and K562/ADM after OKT9-CIL treatment. In addition, DOX in K562/ADM in the free DOX treatment was efficiently excreted by 54% within 120 min of incubation, whereas almost all DOX supplied by OKT9-CIL remained uncleared. Fluorescence microscopic observation showed that OKT9-CIL was internalized into juxtanuclear vesicles in K562/ADM cells. These results suggest that OKT9-CIL has a potency to accumulate DOX, resulting in augmentation of DOX cytotoxicity in DOX-resistant tumour cells.
immunoliposomes, CILs), which target tumour-associated antigens, immunoselectively bind to the corresponding tumour cells and are then internalized, resulting in an increase in the intracellular level of DOX (Tanaka et al, 1989; Suzuki et al, 1994 Suzuki et al, , 1995a . Thus CIL-targeting cells with multidrug-resistant phenotype could lead to a distinct intracellular DOX distribution that may result in the decreased excretion of DOX.
A membrane transferrin receptor (TFR) is associated with cell growth in malignant cells and some normal cells (Hamilton et al, 1979; Trowbridge and Omary, 1981) and is internalized into cells by endocytosis through the binding of transferrin or anti-TFR antibodies (Weissman et al, 1986; Esserman et al, 1989; Girones and Davis, 1989) . Thus TFR possess properties suitable for a target antigen for endocytosis of CILs.
In the present study, changes in the intracellular fate of DOX and its cell growth-inhibitory effect were determined after exposure of a DOX-resistant human leukaemia cell to an anti-TFR CIL. The results obtained indicated a possible advantage of the approach for overcoming multidrug resistance in tumour cells. (2 x 105) were mixed with CIL in a final DOX concentration of 30 gg ml-' in the presence or absence of OKT9-lgG (final concentration of 1 mg ml-1) in 0.2 ml, of SP medium, containing 1% sodium azide for 1 h at 370C. Sodium azide was added to neutralize the effect of endocytosis on the binding. After incubation, total cellular DOX was measured by fluorometry as described in Materials and methods. Columns and bars represent the mean and s.e.m. from three determinations respectively Cancer Cell Repository, Tohoku University. SER4 (mouse IgGI), which was raised against a tumour-associated antigen c-erbB-2 product gpl85 , was used as an unrelated control MAb. AL-6 (mouse IgM), which was raised against immunoliposomes, recognized MBPE on liposomes (Suzuki et al, 1992) . MAbs were purified from ascites of mice transplanted with the corresponding hybridoma cells by 50% ammonium sulphate precipitation, followed by protein G affinity chromatography for IgG or gel filtration on Sepharose CL6B for IgM. Cell surface FITC-conjugated AL-6 was prepared to determine cell-surface CIL, by coupling AL-6 with FITC at a molar ratio of 1:50. The molar ratio in the product was about 1:12.
Thiolation of IgG was performed by SPDP substitution at a molar ratio of 1:5 as described previously (Carlsson et al, 1978) .
Preparation of liposomes CIL was prepared as described previously (Suzuki et al, 1995a) . Briefly, a lipid film prepared from a mixture of dipalmitoylphosphatidylcholine (25 ,umol), cholesterol (17.5 ,umol) and MBPE (2.5 ,umol) was suspended in 2 ml of 125 mm ammonium sulphate, 10 mm Hepes and 2 mM EDTA (pH 5.2) and was extruded ten times through 0.1-gm pore size polycarbonate membrane at 45°C to form small, unilamellar liposomes (SULs). Resultant liposome suspension was chromatographed on a Sepharose CL6B-packed column (1.6 x 30 cm) equilibrated with HBS pH 6.8. Liposomes eluted at void volume were collected, and were then incubated with 1 mg of DOX for 1 h at 45°C. The liposomes were separated from unencapsulated (free) DOX by Sepharose CL6B chromatography as described above, and were then incubated with 2 mg of thiolated IgG for 1 h at 37°C followed by an additional incubation with 5 tl of 2-mercaptoethanol for 30 min. Antibody-coated DOX-encapsulated liposomes (CILs) were purified by Sepharose CL6B chromatography with HBS pH 7.4, sterilized by filtration through a 0.2-gm pore size polycarbonate membrane, and then stored at 4°C until use. Contents of lipid, antibody and DOX in liposomes were determined as described previously (Hashimoto et al, 1983; Tanaka et al, 1989 OKT9-CIL (C-F) at 370C or 40C, respectively, for 1 h. Cells were washed with ice-cold PBS and then further incubated at 370C in SP medium for 0 min (A-C) or 2 h (C-F) in the presence (D) or absence (A-C, E and F) of 1% sodium azide. Cells were washed twice with ice-cold PBS and were immediately observed for DOX fluorescence by fluorescence microscopy (Olympus, Tokyo, Japan, BH-2) with <570 nm cut filter for emission of DOX fluorescence. (A) K562; (B-F) K562/ADM. F is a phase-contrast micrograph of the identical field to E. Bar in F = 1.0 ,um. Magnifications of all micrographs are the same conditions as described in the legends to the figures. After washing twice with ice-cold PBS, cells were mixed with 0.3 M hydrochloric acid, 50% ethanol to extract DOX, and then incubated for 20 min at 37°C. After centrifugation at 500 g for 10 min, the fluorescence intensity of DOX (and its metabolites) in the supernatant was determined fluorometrically at 480 nm (excitation) and 580 nm (emission). An external standard curve for DOX was obtained by plotting the percentage recoveries of DOX from control samples mixed with known doses of DOX.
Flow cytometric analysis
Flow cytometry allows convenient quantification of lower level cellular DOX using a smaller number of cells than with fluorometry, although it provides information only on relative fluorescence intensity of the cells. Thus, we used it to determine ( Figure 5 ) the amount of cellular DOX under the detection limit in fluorometry.
Cells were treated with free DOX solution or CIL suspension in SP medium for 2 h at 4°C with vortexing at 15-min intervals, then washed twice with ice-cold PBS and reincubated for 0-2 h at 37°C in SP medium. After incubation, cells were washed with ice-cold PBS and were divided into two aliquots. An aliquot of the cells was analysed for total cellular DOX and others were analysed for cell-surface CIL. To determine the total DOX level, the cells were immediately analysed by a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA) with excitation at 488 nm and emission at 545-590 nm for DOX fluorescence. To determine cell-surface CIL, the cells were further treated with FITC-AL-6 (50 ,ug ml-') for 1 h at 4°C. After washing twice with PBS, the cell fluorescence was analysed by a flow cytometer as described above except for emission at 515-545 nm (for FITC fluorescence). In both cases, the fluorescence intensity of 5000 viable cells for each sample was recorded. All determinations were performed at a similar detection sensitivity. Mean 
RESULTS
Binding of OKT9-CIL to target cells was determined and compared with a non-reactive control, SER4-CIL (Figure 1 ). OKT9-CIL showed binding to K562 and K562/ADM that was respectively 26 and 17 times higher than binding of SER4-CIL. Binding was inhibited by more than 85% with an excess amount of OKT9 IgG (thinly hatched columns in Figure 1) Figure 2A and B), but the rates of the decrease were higher in K562 (68% at 120 min) than in K562/ADM (37% at 120 min). The decrease in total cellular DOX level was, however, within 5% of the initial value in both cells (open circles in Figure 2A and B). This process did not occur in fixed cells (closed symbols in Figure 2 ) and was suppressed in the presence of some endocytosis inhibitors (Berinstein et al, 1987; Collins et al, 1989) , such as sodium azide, ammonium chloride, chloroquin and colchicine (data not shown). Thus, the decrease in CIL on the cell surface suggests the endocytosis of CILs. To investigate the intracellular localization of DOX, self-fluorescence of DOX in cells treated with DOX or CIL was observed using fluorescence microscopy ( Figure 3) . In K562 cells treated with free DOX for 2 h at 37°C, bright DOX fluorescence was observed in both the nucleus and cytosol ( Figure 3A) . However, in K562/ADM cells treated with free DOX, only weak fluorescence was observed in perinuclear vesicles ( Figure 3B ). When K562/ADM cells were treated with OKT9-CIL at 4°C, liposomal DOX fluorescence was observed as a ring shape indicating the localization of DOX on the cell surface (Figure 3c) . Prolonged incubation at 37°C resulted in the accumulation of the fluorescence into juxtanuclear vesicles ( Figure 3E ). These phenomena were inhibited in the presence of sodium azide in the second incubation ( Figure 3D ). K562 treated with OKT9-CIL showed similar phenomena to those shown by K562/ADM as above (data not shown).
In analyses of cell growth inhibition in K562, OKT9-CIL inhibited leucine incorporation in a dose-dependent manner with an IC50 of 0.35 jg DOX ml-' ( Figure 4A , open triangle). This value is simillar to that for free DOX (0.45 jg DOX ml-'). (non-targeting control) showed a far higher IC50 (8 jig DOX ml-' in Figure 4A ), whereas in K562/ADM ( Figure 4B ) OKT9-CIL showed a 3.5 times lower IC ,, (8 ,ug DOX ml-') than free DOX British Journal of Cancer (1997) 76(1) (28 gg DOX ml-'). SER4-CIL did not show any inhibition of leucine incorporation over the dose range. The effects of antibodynon-coated doxorubicin-containing liposomes were similar to those of SER4-CIL in both cells (data not shown). The intracellular level of DOX was also examined by flow cytometry. The cellular DOX level was increased in a dose-dependent manner in both cells treated with free DOX. The values were 15-45 times lower in K562/ADM than in K562 (triangles in Figure SA and C). Whereas DOX levels in cells treated with OKT9-CIL were similar for both cell lines (squares in Figure SA and C), DOX values in cells treated with free DOX were 3-5 times higher in K562/ADM cells (squares and triangles in Figure SC) . Control SER4-CIL resulted in a far lower DOX level than OKT9-CIL in both cells (circles in Figure SA and SC), indicating that DOX uptake from OKT9-CIL was liposomal antibody dependent. Figure SB and D shows the excretion rate of DOX from cells that had been treated with CIL or free DOX. In K562, the DOX level was unchanged during the incubation irrespective of DOX or CIL treatment, whereas in K562/ADM the intracellular DOX level was immediately decreased to 46% of the initial value when DOX was supplied as free DOX; DOX supplied as OKT9-CIL remained close to 100% of the initial value even after 120 min incubation.
DISCUSSION
An anti-TFR CIL, OKT9-CIL, showed specific binding to a DOXresistant leukaemia line, K562/ADM. OKT9-CIL was internalized into juxtanuclear vesicles and retained in the cells, resulting in a cell growth-inhibitory effect on K562/ADM that was 3.5-fold higher than that of free DOX.
Gervasoni et al (1991) (Thierry et al, 1993) .
British Journal of Cancer (1997) DOX-Lip was delivered to the nucleus of parental tumour cells, whereas in resistant cells DOX-Lip diffused homogeneously throughout the entire cytoplasm. These findings differ from our own observations (shown in Figure 3 ) that OKT9-CIL was finally localized in juxtanuclear vesicles in both the parental K562 and the resistant K562/ADM cells. It is noteworthy that the DOX supplied by OKT9-CIL resulted in no DOX efflux even in the resistant K562/ADM ( Figure 5D ). Thus, the vesicles in which OKT9-CIL accumulated may be different from DOX-Liplocalizing vesicles. Considering the transferrin recycling process (Matthay et al, 1989) , these OKT9-CIL-accumulating vesicles might be specifically induced by a TFR-mediated liposome-cell interaction. DOX resistance has been reported to be overcome by verapamil via inhibition of DOX efflux (Tsuruo et al, 1981 (Tsuruo et al, , 1982 . Verapamil also augments the cytotoxicity of DOX-Lip in resistant cells (Sadasivan et al, 1991) . However, in the present study, the growthinhibitory effect of OKT9-CIL on K562/ADM was not augmented by verapamil (data not shown). This suggests the possibility that the OKT9-CIL inhibited cell growth by a different mechanism from that for free DOX or Lip-DOX.
Drug resistance has also been reported to be inhibited by low cytosolic pH (Willingham et al, 1986; Hindenburg et al, 1989; Marquardt and Center, 1992) . This suggests that the drug efflux mechanism is associated with the ionization of drugs within cells. In our system, the DOX encapsulated in the inner space of CIL is thought to be highly concentrated as the sulphate salt to form a gel (Lasic et al, 1992) . Thus, this gelated, ionized DOX may be one of the reasons why the DOX in OKT9-CIL escaped from the efflux mechanism in K562/ADM.
In general, liposomal drugs have some pharmacological advantages, such as low immunogenicity, deposit ability and tissuespecific localization. With the in vivo application of liposomal drugs, the uptake of liposomes by reticuloendothelial tissues may have limited the effect. In order to overcome this difficulty, we have recently prepared a CIL coated with polyethyleneglycol (Suzuki et al, 1995b ). This CIL not only showed specific cytotoxicity to tumour cells but also remained in the circulation for a long time. This technique is also applicable to OKT9-CIL. Thus, overall, OKT9-CIL has potential to be a useful therapeutic reagent in the treatment of DOX-resistant TFR-positive tumours. ABBREVIATIONS DOX, doxorubicin; CIL, chemoimmunoliposome(s), doxorubicinencapsulated immunoliposome(s); Hepes, N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid; MAb, monoclonal antibody; SPDP, N-hydroxysuccinimidyl-3-(2-pyridyldithio)-propionate; FITC, fluorescein isothiocyanyl; PBS, phosphate-buffered saline; FCS, fetal calf serum; SP medium, standard medium:PBS (1:1) containing 5% FCS; HBS, Hepes-buffered saline, 20 mM Hepes, 150 mm sodium chloride (pH 7.4); MBS, m-maleimidobenzoyl-Nhydroxysuccinimido ester; MBPE, MBS derivative of dipalmitoylphosphatidylethanolamine.
